is employing Proteros
biostructures to support structure-based discovery of small molecule drugs. Proteos will receive research fees and milestones.
Initially, Proteros will leverage its expertise in gene-to-structure projects and its technologies to solve the 3-D structure of an undisclosed target together with its related proteins.
After the establishment of these crystallography systems, Proteros will screen fragments and compounds supplied by UCB with the objective of confirming the binding modes to the proteins. This will facilitate medicinal chemistry research and optimization of small molecules, the companies say.